These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 37284874)

  • 1. Long-term treatment of chronic kidney disease patients with anemia using hypoxia-inducible factor prolyl hydroxylase inhibitors: potential concerns.
    He J; Jia Z; Zhang A; Bai M
    Pediatr Nephrol; 2024 Jan; 39(1):37-48. PubMed ID: 37284874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
    Sugahara M; Tanaka T; Nangaku M
    Pharmacol Ther; 2022 Nov; 239():108272. PubMed ID: 36031160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
    Mima A
    Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients.
    Wang B; Yin Q; Han YC; Wu M; Li ZL; Tu Y; Zhou LT; Wei Q; Liu H; Tang RN; Cao JY; Lv LL; Liu BC
    Ren Fail; 2020 Nov; 42(1):912-925. PubMed ID: 32869703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
    Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
    Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease.
    Zhao H; Li P; Zhang HL; Jia L
    Ren Fail; 2023; 45(2):2258986. PubMed ID: 37724564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors
    Yang J; Xing J; Zhu X; Xie X; Wang L; Zhang X
    Front Endocrinol (Lausanne); 2023; 14():1131516. PubMed ID: 37008953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
    Kurata Y; Tanaka T; Nangaku M
    Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):414-422. PubMed ID: 32452915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac and Kidney Adverse Effects of HIF Prolyl-Hydroxylase Inhibitors for Anemia in Patients With CKD Not Receiving Dialysis: A Systematic Review and Meta-analysis.
    Zheng Q; Wang Y; Yang H; Sun L; Zhang P; Zhang X; Guo J; Liu YN; Liu WJ
    Am J Kidney Dis; 2023 Apr; 81(4):434-445.e1. PubMed ID: 36396085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A spotlight on using HIF-PH inhibitors in renal anemia.
    Odawara M; Nishi H; Nangaku M
    Expert Opin Pharmacother; 2024 Jul; 25(10):1291-1299. PubMed ID: 38994698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis.
    Li J; Xie QH; You L; Xu NX; Hao CM
    Pharmacol Res; 2021 Jan; 163():105256. PubMed ID: 33086081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation.
    Wish JB; Eckardt KU; Kovesdy CP; Fishbane S; Spinowitz BS; Berns JS
    Am J Kidney Dis; 2021 Nov; 78(5):709-718. PubMed ID: 34332007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.
    Chen J; Shou X; Xu Y; Jin L; Zhu C; Ye X; Mei Z; Chen P
    Aging (Albany NY); 2023 Mar; 15(6):2237-2274. PubMed ID: 36988549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.
    Sanghani NS; Haase VH
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):253-266. PubMed ID: 31477256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.
    Kaplan JM; Sharma N; Dikdan S
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Patients with Renal Anemia: A Meta-Analysis of Randomized Trials.
    Wen T; Zhang X; Wang Z; Zhou R
    Nephron; 2020; 144(11):572-582. PubMed ID: 32866960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
    Maruno S; Tanaka T; Nangaku M
    Rinsho Ketsueki; 2021; 62(5):371-377. PubMed ID: 34108317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors as a New Treatment Option for Anemia in Chronic Kidney Disease.
    Bartnicki P
    Biomedicines; 2024 Aug; 12(8):. PubMed ID: 39200348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease.
    Ha JT; Hiremath S; Jun M; Green SC; Wheeler DC; Coyne DW; Perkovic V; Badve SV
    NEJM Evid; 2024 Sep; 3(9):EVIDoa2300189. PubMed ID: 39186635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors.
    Locatelli F; Minutolo R; De Nicola L; Del Vecchio L
    Drugs; 2022 Nov; 82(16):1565-1589. PubMed ID: 36350500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.